The FDA has approved Astellas' Vyloy to treat gastric cancer. Egypt has been certified malaria-free by WHO. A Tennessee court ...

Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in ...

The FDA has approved zolbetuximab-clzb (VYLOY) as a first-line targeted therapy, in combination with chemotherapy, for the ...

Recent health news includes FDA's approval of Astellas' gastric cancer therapy, the resignation of CVS Health CEO Karen Lynch ...

The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...

Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and ...

Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...

Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

Astellas Pharma's drug Vyloy was approved for treatment of advanced gastric and gastroesophageal junction cancer by the Food and Drug Administration.

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...